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1  | INTRODUC TION
Polycystic ovary syndrome (PCOS) is a common endocrine dis-
order associated with hyperandrogenism, insulin resistance and 
dyslipidaemia. These disturbances lead to an increased risk of car-
diometabolic disease including type 2 diabetes.1 The underlying 
drivers of this process are unclear although chronic inflammation 
may play an important role.2
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Abstract
Objective: Polycystic ovary syndrome (PCOS) is associated with metabolic risk. 
Complement proteins regulate inflammation and lipid clearance but their role in 
PCOS-associated metabolic risk is unclear. We sought to establish whether the com-
plement system is activated in PCOS in the fasting and postprandial state.
Design: Case-control study.
Patients: Fasting complement levels were measured in 84 women with PCOS and 
95 healthy controls. Complement activation post-oral fat tolerance test (OFTT) was 
compared in 40 additional subjects (20 PCOS, 20 controls).
Measurements: Activation pathway (C3, C4, C3a(desArg), factor B, factor H, proper-
din, Factor D) and terminal pathway (C5, C5a, terminal complement complex [TCC]) 
proteins were measured by commercial or in-house assays.
Results: Fasting C3, C3a(desArg) and TCC concentrations were increased in insulin-
resistant (adjusted differences: C3 0.13 g/L [95%CI 0-0.25]; C3a(desArg) 319.2 ng/
mL [19.5-619]; TCC 0.66 μg/mL [0.04-1.28]) but not in insulin-sensitive women with 
PCOS. C3 and factor H levels increased with obesity. Post-OFTT, C3 and C4 levels 
increased to a similar extent in PCOS subjects and controls, whist factor H levels in-
creased more in women with PCOS compared to controls (adjusted differences (area 
under the curve): 12 167 μg min/mL [4942-19 392]), particularly in the presence of 
concomitant obesity.
Conclusions: Activation and terminal complement pathway components are elevated 
in patients with PCOS, especially in the presence of insulin resistance and obesity.
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The complement system is a key regulator of inflammation and 
consists of three activation pathways: classical, alternative and 
lectin, which converge at the level of C3 to form C3 convertases 
(Figure S1). Whilst the classical and lectin pathway convertases de-
pend on C2 and C4 cleavage, the alternative pathway convertase 
requires factor B and factor D. Further activation of the complement 
system through to the terminal pathway involves C5 cleavage and 
leads to formation of the membrane attack complex and its flu-
id-phase by-product, the terminal complement complex (TCC). Both 
positive and negative regulators exist, including the alternative path-
way regulators properdin and factor H.
Components of the complement system, notably C3, have 
been shown to be increased in patients with metabolic syndrome,3 
type 2 diabetes4 and cardiovascular disease.5 Postprandially, C3 
activation has been shown to increase lipid clearance and stor-
age in human adipocytes6,7; C3a, a product of C3 activation, is 
rapidly cleaved in plasma to form C3a(desArg). C3a(desArg) binds 
to its receptor, C5L2, on adipocytes to increase triglyceride syn-
thesis.6,8,9 Chylomicrons, transporters of lipids in the postprandial 
period, have been shown to increase C3 activation,10 an event that 
is regulated in vivo by factor H.11 Furthermore, activation path-
way components (C3, C4, factor D and factor B) alter after a meal, 
and postprandial C3 responses differ in patients with and without 
cardiometabolic disease.12-15 These findings suggest that dysreg-
ulated postprandial complement activation may influence meta-
bolic health and contribute to the development of cardiometabolic 
pathology.
Only a few studies have examined the complement system 
in women with PCOS, finding increased levels of factor D16 and 
C3a(desArg),17,18 and increased18,19 or no difference20,21 in C3 
levels compared to matched controls. However, many of these 
studies are limited by fasting measurements only and small sam-
ple sizes. We therefore sought to establish whether the comple-
ment system is activated in women with PCOS and whether any 
abnormalities are evident in the postprandial as well as the fast-
ing state.
2  | MATERIAL S AND METHODS
2.1 | Overall study design
We undertook the study in two parts. We firstly compared fasting 
plasma complement protein levels between insulin-resistant pa-
tients with PCOS (n = 84) and healthy controls (n = 95; cohort 1). 
Plasma samples, maintained at −80°C, were obtained from our pre-
vious study in which detailed anthropometric, metabolic and cardio-
vascular phenotyping was undertaken.22 We then compared fasting 
and post-oral fat tolerance test (OFTT) complement levels in PCOS 
women (n = 20) and healthy controls (n = 20; cohort 2), in order to 
determine any contribution of postprandial lipaemia to complement 
activation.
2.2 | Inclusion and exclusion criteria
For both cohorts, patients with PCOS (aged 16-45 years) were 
recruited from a departmental database or from outpatients at-
tending the University Hospital of Wales. A diagnosis of PCOS was 
made according to the Rotterdam criteria, with congenital adrenal 
hyperplasia, androgen-secreting tumours, Cushing's syndrome, 
thyroid disease and hyperprolactinaemia excluded by biochemi-
cal testing. Subjects were also excluded if they were pregnant, 
breastfeeding or had a history of hypertension, hyperlipidaemia or 
diabetes, or current or previous (within 3 months) use of gluco-
corticoids, lipid-lowering agents, antihypertensives, antidiabetics 
or anti-obesity drugs. Healthy volunteers were recruited by adver-
tisement in the local press, and among students and staff within 
our Institution. Healthy volunteers had regular menstrual cycles 
(every 27-32 days) and their healthy state was established by his-
tory, physical examination and hormonal evaluation (thyroid func-
tion, prolactin, testosterone and 17-hydroxyprogesterone); those 
with features of hirsutism or a family history of PCOS were ex-
cluded. For cohort 1, in the PCOS group there were 15 current 
smokers and 12 ex-smokers (32.1%) compared with 11 current 
smokers and 19 ex-smokers among the healthy volunteers (31.6%). 
Nineteen subjects with PCOS (22.6%) were taking a combined oral 
contraceptive pill compared with 28 (29.5%) healthy volunteers. 
For cohort 2, in the PCOS group there were two current smokers 
and one ex-smoker (15%) compared with one current smoker and 
two ex-smokers among the healthy volunteers (15%). Of the PCOS 
group, 8 (40%) were taking a combined oral contraceptive pill com-
pared with 7 (35%) healthy volunteers. The study was approved by 
Cardiff and Vale University Health Board, Cardiff University and 
the South East Wales Research Ethics committee (reference num-
ber 08/WSE/04/53). All subjects gave written informed consent 
prior to study commencement.
2.3 | Postprandial study protocol and assessment of 
insulin sensitivity
Cohort 2 subjects attended our Clinical Research Facility at 
09:00 hours after an overnight fast. The standard OFTT meal 
comprised fresh cream with 40% (weight by volume; w/v) fat 
emulsion (polyunsaturated:saturated fat ratio of 0.10) that con-
tained 0.001% (w/v) cholesterol and 3% (w/v) carbohydrates and 
had a total energy content of 3700 kcal/L.13 The fresh cream was 
given at a dose of 50 g fat and 3.75 g glucose/m2 body surface 
(approximately 200 mL). Subjects were allowed up to 10 minutes 
to consume the meal. During the test, participants remained su-
pine and were only allowed to drink mineral water. Blood sam-
ples were obtained at 0 (fasting baseline), 30, 60, 120, 180 and 
240 minutes after consuming the meal, collected into sodium 
EDTA (2 mg/mL) then centrifuged immediately for 15 minutes 
at 800 g at 4°C. Plasma was separated and stored in aliquots at 
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−80°C until analysis. The areas under the curves (AUC) for tri-
glycerides and complement components were calculated using 
the trapezoid method.
On a separate day, after an overnight fast, subjects in cohort 
2 underwent basal sampling for measurement of lipids and testos-
terone. Subjects subsequently underwent a standard 75 g oral glu-
cose tolerance test. Glucose and insulin were measured at 0, 30, 
60, 90 and 120 minutes. The AUCs for insulin and glucose were 
calculated using the trapezoid method. The homeostatic model 
assessment method was also used to estimate insulin resistance 
(HOMA-IR).
2.4 | Anthropometric measurements
Height, weight, waist and hip circumference were measured accord-
ing to our published protocol.23 Abdominal subcutaneous (SF) and 
visceral (VF) fat areas were measured by X-ray computed tomogra-
phy (CT; Hawkeye, GE Medical Systems) as previously described.23 
CT images were segmented into fat and nonfat areas according to 
our previously published protocol.23
2.5 | Biochemical analysis
Plasma total cholesterol, HDL and triglyceride levels were meas-
ured using an Aeroset automated analyser (Abbott Diagnostics). 
Insulin levels were assessed using an immunometric assay specific 
for human insulin (Invitron), and glucose was measured using the 
Aeroset chemistry system (Abbott Diagnostics). Total testosterone 
was measured by liquid chromatography-tandem mass spectrom-
etry (Quattro™ Premier XE triple quadrupole tandem mass spec-
trometer; Waters Ltd). Plasma C3 and C4 levels were quantified by 
nephelometry on a Beckman BN11 nephelometer in the University 
Hospital of Wales Clinical Immunology laboratory using commer-
cial standards. The assay working range for C3 was 0.02-4.1 g/L, 
and for C4 was 0.01-1.9 g/L. C5a(desArg), C3a(desArg), factor D 
and properdin were quantified using their respective commercial 
assays from Hycult Biotech, as instructed by the manufacturer. 
Plasma C5, TCC and factor H were all measured using in-house 
ELISA.24-26 All assays used purified protein (either C5, TCC or fac-
tor H) as a standard. For C5 ELISA, plates were coated with an 
in-house polyclonal rabbit antihuman C5 antibody (8 μg/mL, 
100 µL/well, in bicarbonate buffer [pH 9.6]), blocked in 2% (w/v) 
bovine serum albumin (BSA; blocking buffer), and then incubated 
with plasma samples diluted one in 600 in blocking buffer. Mouse 
monoclonal antihuman C5 (MBI-C5-3; 5 μg/mL) was used to detect 
bound C5, followed by donkey antimouse IgG horseradish peroxi-
dase (HRP; 1 in 2500).
For TCC quantification, plates were coated with an in-house 
anti-C9 neo-antibody (B7), used at 4 µg/mL, 100 µL/well. After 
blocking with 2% (w/v) BSA, plasma samples were diluted 1:6 in 
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C8 (clone E2, in-house) was added to wells for detection of TCC 
(100 µL; 2 µg/mL). For total factor H ELISA, plates were coated 
with affinity-purified rabbit antifactor H IgG diluted in bicarbon-
ate coating buffer (pH 9.6) at 5 μg/well. After blocking with 1% 
(w/v) BSA, plasma samples were diluted 1:6000 in blocking buffer. 
HRP-labelled affinity-purified rabbit antihuman factor H (100 µL; 
1 mg/L) was used to detect total factor H. Of note, many papers 
quote higher levels of serum factor H; the extinction coefficient 
for factor H standards on which our normal range is based has 
been validated previously.26
2.6 | Statistical analysis
Linear regression models were used to assess differences in mean bi-
omarker levels between PCOS and control groups, adjusting for age, 
F I G U R E  1   Influence of BMI on fasting C3, C3adesArg and TCC concentrations in PCOS and control subjects (cohort 1). Boxplots of C3 
(A), C3adesArg (B) and TCC levels in PCOS subjects and metabolically healthy controls. Data grouped according to BMI (lean: BMI 18.5-
24.99; overweight: BMI 25-29.99 and obese: BMI ≥ 30 kg/m2). Middle lines show the medians of the data and the boxes highlight the 25th 
and 75th percentiles (Quarter 1 and Quarter 3). C3 levels were significantly higher in obese subjects with PCOS compared to obese controls 
(mean difference ± SEM; 0.222 ± 0.099 g/L, P < .05). TCC: terminal complement complex. n = 84 PCOS, n = 95 Controls
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BMI and smoking wherever the latter were found to have explana-
tory value. Best fitting models were selected on the basis of Akaike's 
information criterion (AIC). A two-tailed P-value of <.05 was con-
sidered significant. All analyses were performed with the GraphPad 
Prism version 5 Windows and the R language and environment for 
statistical computing.
3  | RESULTS
3.1 | Fasting complement concentrations in insulin-
resistant PCOS subjects and healthy controls
The clinical, metabolic and anthropometric characteristics of cohort 
1 are shown in Table SI1. As anticipated, PCOS women had higher 
androgen levels and worse insulin sensitivity, even after adjust-
ment for age and BMI. Table 1 shows the concentration of plasma 
complement components and activation products in PCOS subjects 
and controls, before and after adjustment. Plasma C3, C3a(desArg), 
C3a(desArg)/C3 ratio and TCC levels were significantly increased 
in the PCOS group compared to controls, even after adjustment. 
Factor B, factor H and factor D were all significantly increased in 
PCOS before, but not after, adjustment for BMI, age and smoking. 
Conversely, properdin was significantly increased in the PCOS group 
but only after adjusting for age, BMI and smoking. Fasting levels of 
C3, C3a(desArg), C4, FH and TCC were unaffected by oral contra-
ceptive status (data not shown).
Figure 1 shows the fasting plasma concentrations of C3, 
C3a(desArg) and TCC in PCOS subjects and healthy controls, strat-
ified according to BMI. C3 levels increased across BMI categories 
in both groups but between-group differences were only appar-
ent in obesity (mean difference ± SEM; 0.22 ± 0.1 g/L; P < .05). In 
contrast, C3a(desArg) and TCC levels were not affected by BMI.
3.2 | Associations of fasting complement 
concentrations and metabolic parameters
The associations between circulating complement levels and a range 
of anthropometric and metabolic risk measures are shown in Table S2. 
Across the whole cohort (PCOS and controls), triglycerides, and to a 
lesser extent LDL cholesterol, correlated strongly with early complement 
pathway components and activation products but weakly with terminal 
components and activation products (C5, C5a(desArg) and TCC). Both 
early and late complement pathway components were significantly as-
sociated with both visceral and subcutaneous fat area. HOMA-IR was 
most strongly associated with C3, factor H and properdin.
3.3 | Fasting complement concentrations in insulin-
sensitive PCOS subjects and healthy controls
Table S3 summarizes the clinical and metabolic characteristics of 
the PCOS and healthy control groups in cohort 2. PCOS and healthy 
volunteers were well matched for age and BMI. As expected, testos-
terone concentrations were increased in PCOS subjects compared 
with controls but measures of insulin resistance (insulin AUC and 
HOMA-IR) were not different between groups. Furthermore, in con-
trast to cohort 1, there were no differences in fasting complement 
concentrations between groups (Table S4).
3.4 | Effect of postprandial lipaemia on 
plasma complement concentrations in PCOS 
subjects and controls
To compare the effects of postprandial lipaemia on comple-
ment secretion, PCOS subjects and healthy volunteers in cohort 
F I G U R E  2   Effects of postprandial lipaemia on triglyceride and complement concentrations in PCOS and control subjects. Postprandial 
triglyceride (A), factor H (B), TCC (C), C3 (D), C4 (E), properdin (F) and C3adesArg (G) levels in response to OFTT in PCOS cohort and control 
groups (cohort 2). Data are mean ± SEM. n = 20 PCOS, n = 20 Controls
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2 underwent an OFTT. As expected, plasma triglyceride levels 
increased significantly from baseline in both PCOS and control 
groups (Figure 2A), reaching maximum levels (Tmax) at 240 minutes 
(mean ± SEM; 0.86 ± 0.13 mmol/L [baseline] vs 1.6 ± 0.24 mmol/L) 
and 180 minutes (mean ± SEM; 0.75 ± 0.12 mmol/L [baseline] vs 
1.45 ± 0.26 mmol/L) post-OFTT, respectively.
There was a significant difference in the postprandial factor H 
response between PCOS and control groups (Figure 2B; Table S5). 
In controls, factor H levels fell sharply from baseline during the 
first hour post-OFTT (mean ± SEM; 250.9 ± 21.49 µg/mL vs 
173.6 ± 15.26 µg/mL). In contrast, in the PCOS group, factor H levels 
increased 30 minutes post-OFTT. Consequently, the AUC for factor 
H was significantly different between PCOS and controls (Table S5).
Postprandial TCC, C3 and C4 (Figure 2C-E), but not properdin 
or C3a(desArg; Figure 2F-G), levels increased from baseline in both 
controls and PCOS subjects, but no differences were observed be-
tween groups (Table S5).
3.5 | Effect of obesity on the complement response 
to OFTT
We subsequently divided the PCOS and control groups into ‘obese’ 
(BMI ≥ 30 kg/m2) and ‘non-obese’ (BMI < 30 kg/m2) groups and 
compared the effects of lipaemia on plasma levels of factor H, 
TCC and C3 in these groups (Figure 3A-C, respectively). Within 
the PCOS group, obesity had a profound effect on both baseline 
levels and AUC for factor H. Fasting factor H levels and AUC were 
both markedly increased in obese vs non-obese PCOS subjects 
(mean ± SEM; baseline: 362.1 ± 56.41 µg/mL vs 204.3 ± 24.05 µg/
mL, respectively; P < .001, and AUC: 1717 ± 164.1 µg min/mL vs 
1004 ± 54.4 µg min/mL, respectively; P < .0001). Furthermore, 
across the whole cohort, strong correlations were observed be-
tween factor H AUC and each of HOMA-IR, visceral and subcuta-
neous fat area (Figure 4; P < .0001 for all), and in fasting samples 
(cohort 1) between factor H and BMI, regardless of age (Figure 5; 
age 20-30: r2 .43, P < .001 [PCOS] r2 .62, P < .001 [controls]; age 
30-40: r2 .30, P < .001 [PCOS] r2 .44, P < .001 [controls]; age 40-
50: r2 .77, P < .05 [PCOS], r2 .36, P < .001 [controls]). There was no 
evidence of a relationship between factor H AUC and testosterone 
(data not shown). Baseline C3 levels were increased in obese com-
pared to non-obese subjects irrespective of disease status, with C3 
concentrations increasing gradually across the time course of the 
OFTT in both groups (Figure 3C).
4  | DISCUSSION
In this analysis of complement proteins and activation products in 
young women, we find evidence of complement dysregulation in 
F I G U R E  3   Influence of obesity on factor H, C3 and TCC responses to postprandial lipaemia. Postprandial factor H (A), TCC (B) and C3 (C) 
responses to OFTT in obese (BMI ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2) PCOS and control subjects (cohort 2). Obese and non-obese 
controls. n = 20 PCOS, n = 20 Controls
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patients with PCOS (Figure S2). Activation of the complement cas-
cade was evident in the fasting state as well as postprandially and 
involved both the activation (C3, C3(adesArg), factor H) and terminal 
pathways (C5a(desArg), TCC). Furthermore, complement dysregula-
tion was most pronounced in metabolically unhealthy subjects and 
correlated with both obesity and insulin sensitivity.
Our findings are consistent with some17-19 but not all20,21 pre-
vious studies in which C3 and C3a(desArg) levels were found to be 
increased in women with PCOS compared to controls. C3a(desArg), 
also known as acylation-stimulating protein (ASP), increases energy 
storage through a number of actions, including enhanced glucose 
uptake, reduced lipolysis and increased triglyceride clearance.27 
Consistent with these observations, C3a(desArg) and C3 levels are 
increased in subjects with obesity and type 2 diabetes,28,29 whilst 
C3 knockout mice display reduced body weight and fat mass.27 
Longitudinal human data have additionally shown that changes in 
C3 levels are positively associated with increase in BMI,30 incident 
obesity31 and metabolic syndrome, implying a possible role for com-
plement dysregulation in human obesity.
C3a(desArg) is synthesized in a two-step process involving C3, 
factor B and factor D; cleavage of the parent molecule C3 generates 
C3a, which subsequently undergoes desargination of the carboxyl 
terminus to generate C3a(desArg). In contrast to C3, fasting levels 
of factor B and factor D were only elevated in our PCOS subjects in 
unadjusted analyses, suggesting that obesity was the main factor ac-
counting for these increases. This accords with similar findings from 
Daan et al,32 who found no difference in factor D levels in either hy-
perandrogenic or normoandrogenic PCOS subjects compared with 
unaffected controls, and with other studies showing elevated factor 
B and D concentrations in obesity.28,33,34 In contrast, Gursoy Calan 
et al16 found that factor D levels were elevated in women with PCOS 
compared with age- and BMI-matched controls and that circulating 
concentrations correlated with both BMI and HOMA-IR.
Properdin and factor H are important regulators of alternative 
pathway activation: properdin acts as a stabilizer of C3 convertase 
leading to prolonged complement activation, whilst factor H func-
tions as an inhibitor by dissociating C3 convertase; elevations in both 
reflect alternative pathway dysregulation. Whilst fasting properdin 
F I G U R E  4   Relationship between 
factor H area under the curve (AUC), 
body fat and metabolic parameters. Data 
represent PCOS subjects and controls in 
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concentrations were not different in our unadjusted analyses, proper-
din levels were marginally lower after adjustment for BMI and age. 
In contrast, fasting factor H concentrations were higher in PCOS 
subjects only before adjustment for the group differences in BMI. 
This observation is consistent with previous cross-sectional and lon-
gitudinal studies which have shown positive associations between 
factor H concentrations and adiposity.30,35 We also found elevated 
TCC concentrations in women with PCOS, indicating increased ter-
minal pathway activation. Increased TCC levels are likely caused by 
alternative pathway dysregulation since inhibition of the alternative 
pathway reduces TCC concentrations by >80%.36,37
In view of the differences we observed in fasting complement 
protein levels of both activation and terminal pathways, we sub-
sequently sought to compare the kinetics of complement protein 
generation in response to a fatty meal. We were keen to focus 
on the impact of lipaemia since postprandial triglycerides predict 
cardiovascular risk better than fasting levels,38 not least because 
humans exist in a postprandial state for most of the day. Lipaemic 
challenge resulted in a substantial increase in triglyceride levels 
whilst C3, C4 and TCC increased to a similar extent in both groups. 
In contrast, whilst factor H levels fell in controls, an acute rise was 
observed in PCOS subjects, notably in the presence of co-existing 
obesity. Several complement components have been implicated 
in lipid metabolism. Chylomicrons, which transport dietary lipids, 
can spontaneously activate the alternative pathway and become 
coated in C3 opsonic fragments.11 C3 fragments are also present 
in other lipoproteins, including apolipoprotein-A1 (which associ-
ates with chylomicrons), and in HDL.39 Factor H regulates chylomi-
cron-induced C3 activation during lipid storage11 and alternative 
pathway complement activation on HDL.40 Obesity appeared to 
be a significant driver for the elevated factor H levels in our PCOS 
subjects in both the fasting and postprandial state. Insulin resis-
tance also correlated significantly with postprandial factor H area 
under the curve. Since adiposity and insulin resistance are inti-
mately linked, it is difficult to establish which of these parameters 
is the dominant driver. However, it is interesting to note that not 
F I G U R E  5   Correlation between fasting factor H concentrations and BMI. Data represent correlations between factor H levels and BMI in 
different age groups in PCOS subjects (triangles, dashed line) and controls (circles, solid line; cohort 1). Factor H levels correlated positively 
with BMI in both PCOS (n = 84) and controls (n = 95) in all age groups
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only does insulin resistance correlate with omental fat factor H 
expression35 but also that addition of factor H to freshly isolated 
pancreatic islet cells reduces insulin secretion.41 It is thus conceiv-
able that a bidirectional effect may exist, whereby reduced insulin 
sensitivity is both a mediator and consequence of alternative path-
way complement activation.
In contrast to C3, postprandial C3a(desArg) levels did not 
alter from baseline. At first glance, this may seem surprising given 
the role of C3a(desArg) in increasing lipid uptake and storage. 
However, other studies have also shown unaltered circulating 
C3a(desArg) levels in response to a fat meal.12,42 This may be at-
tributable to local as opposed to systemic C3a(desArg) formation 
and rapid adipocyte uptake upon subsequent C5L2 receptor bind-
ing. In line with this, veno-arterial gradient studies have confirmed 
that C3a(desArg) is generated in vivo by human adipocytes and 
that this production is exaggerated postprandially, especially in 
the presence of obesity.43,44 Indeed, adipocytes are an import-
ant source of complement components, particularly those of the 
alternative pathway. Both visceral and subcutaneous adipose tis-
sue are known to produce and secrete C3, C4, factor D, proper-
din and factor H, creating an environment for local generation of 
C3a(desArg).29,35,45
In light of our findings of complement dysregulation in women 
with PCOS, it would be interesting to explore whether therapeutic 
strategies to reduce alternative pathway activation might alleviate 
or prevent complications associated with PCOS such as metabolic 
syndrome, type 2 diabetes and cardiovascular disease. In this con-
text, it is interesting to note that C3a(desArg) levels are reduced 
by weight loss46 and physical activity47 in obesity, whilst C3 and 
C3a(desArg) levels fall in response to metformin therapy in women 
with PCOS.18 Statins have also been shown to reduce C3 and 
C3a(desArg) levels in patients with cardiovascular risk, both in the 
fasting and postprandial state.15,48,49 Additional studies examining 
the effects of new compounds that selectively reduce alternative 
complement pathway activation50 would be of therapeutic interest, 
not only in PCOS but also in other cardiometabolic disorders asso-
ciated with enhanced complement activation. However, any such 
treatments would need a careful evaluation of safety, especially 
with regard to fertility and pregnancy, in this young, reproductive 
age population.
Our study has both strengths and limitations. To our knowledge, 
this is the most comprehensive analysis to date of the complement 
system in patients with PCOS, benefiting from careful anthropomet-
ric and metabolic characterization in addition to measurements in 
the postprandial as well as the fasting state. Nevertheless, whilst 
we intentionally sought to compare postprandial complement acti-
vation kinetics in a carefully matched population of PCOS subjects 
and controls, our study was limited by the absence of an additional 
group of insulin-resistant women with PCOS. We were also limited 
to a 4-hour study window after the fat challenge.
In summary, we demonstrate evidence of complement activa-
tion and dysregulation in women with PCOS which is exacerbated 
in the presence of obesity and insulin resistance. We show that this 
extends to the terminal pathway and is evident in the postprandial 
as well as the fasting state. These disturbances have implications for 
lipid clearance, inflammation and insulin sensitivity and suggest that 
studies are needed to explore whether interventions aimed at reg-
ulating complement activation in PCOS may be helpful in reducing 
cardiometabolic risk.
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